amlodipine/valsartan / Generic mfg. - LARVOL DELTA

OPTION TREAT: Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (clinicaltrials.gov) - P3 | N=702 | Completed | Sponsor: Hospital Israelita Albert Einstein | Recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ May 2025 | Trial primary completion date: Dec 2023 ➔ Mar 2025

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension

Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE) (clinicaltrials.gov) - P3 | N=8518 | Recruiting | Sponsor: Hospital Moinhos de Vento | N=12268 ➔ 8518 | Trial completion date: Dec 2026 ➔ Dec 2030 | Trial primary completion date: Dec 2025 ➔ Dec 2029

Enrollment change • Trial completion date • Trial primary completion date • Cardiovascular • Cognitive Disorders

POLYPILL AND RISKOMETER TO PREVENT STROKE AND COGNITIVE IMPAIRMENT IN PRIMARY HEALTH CARE – FINAL RESULTS OF THE PROMOTE PILOT STUDY (ESOC 2024) - "Background and aims: PROMOTE study aims to assess whether a polypill (valsartan 80mg, amlodipine 5mg, and rosuvastatin 10mg) used alone or in combination with lifestyle modification (through Stroke Riskometer) will reduce the incidence of stroke and cognitive impairment in a population of individuals at low to moderate risk of stroke. The final results of the study will be presented at ESOC"

Clinical • Cardiovascular • Hypertension

CARDIAC AND RENAL MANIFESTATIONS OF FABRY DISEASE IN A HETEROZYGOUS FEMALE (ACC 2024) - "Her medications are valsartan, amlodipine, gabapentin, and atorvastatin. FD is treatable with disease-specific treatment ERT or chaperone therapy. Therefore, the early diagnosis of FD is crucial for reducing morbidity and mortality. Screening of high-risk populations (e.g., patients with unexplained left ventricular hypertrophy, young patients with unexplained stroke, and patients with unexplained renal failure, proteinuria, or microalbuminuria) yields superior results."

Cardiovascular • Dyslipidemia • Fabry Disease • Fatigue • Genetic Disorders • Hepatology • Inflammation • Metabolic Disorders • Pain • Renal Disease

Safety and efficacy of candesartan versus valsartan combined with amlodipine on peripheral and central blood pressure. (PubMed, Hipertens Riesgo Vasc) - "The two treatment groups did not exert significant efficacy in lowering heart rate (HR) and augmentation index% (AIx%). To conclude, the amlodipine 10mg/candesartan 16mg combination was non-inferior to the amlodipine 10mg/valsartan 160mg combination in terms of reducing peripheral and CBP over time."

Journal

Bioequivalence Study of Amlodipine/Valsartan 10/160 mg Film Coated Tablets (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: International Bio service

New P1 trial

Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis. (PubMed, Clin Cardiol) - "The results of the network meta-analysis showed that a total of 11 single-pill combination antihypertensive drugs were included, namely: Amlodipine/valsartan, Telmisartan/amlodipine, Losartan/HCTZ, Candesartan/HCTZ, Amlodipine/benazepril, Telmisartan/HCTZ, Valsartan/HCTZ, Irbesartan/amlodipine, Amlodipine/losartan, Irbesartan/HCTZ, and Perindopril/amlodipine. Based on Ranking Plot of the Network, we can conclude that single-pill combination antihypertensive drugs are superior to monotherapy, and ARB/CCB combination has better advantages than other SPC in terms of systolic blood pressure, diastolic blood pressure, blood pressure control rate, and diastolic response rate. However, due to the small number of some drug studies, the lack of relevant studies has led to not being included in this study, which may impact the results, and readers should interpret the results with caution."

Journal • Retrospective data • Review • Cardiovascular • Hypertension

Pheochromocytoma - A Silent Killer (ENDO 2023) - "Interestingly, prior to admission, patient's BP was not controlled (ranges 140s-170s/60s-90s) even on three antihypertensives (Hydrochlorothiazide (HCTZ), Valsartan, & Amlodipine)...On discharge he was maintained on Prazosin, valsartan, and amlodipine for hypertension and Lantus 28-unit qAM along with Aspart 4-unit premeal for diabetes. This case highlights the importance of familiarity with the different presentations of pheochromocytoma (i.e. uncontrolled and challenging hyperglycemia, persistent uncontrolled hypertension, without any obvious physical signs) to healthcare providers as it can be mistreated if left undiagnosed."

Cardiovascular • Diabetes • Dyslipidemia • Endocrine Cancer • Fatigue • Gastrointestinal Cancer • Hepatology • Hypertension • Metabolic Disorders • Neuroendocrine Tumor • Oncology • Pain • Pancreatic Cancer • Solid Tumor • Type 2 Diabetes Mellitus

DINAMICS OF ARTERIAL STIFFNESS USING CAVI INDEX DEPENDS ON ADDED STATIN TO FIXED COMBINATION ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION. (PubMed, J Hypertens) - "The added of statin to fixed combination antihypertensive therapy prevented the progression of arterial stiffness in patients with arterial hypertension."

Journal • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Pulmonary Arterial Hypertension

Polipill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE) (clinicaltrials.gov) - P3; N=12268; Not yet recruiting; Sponsor: Hospital Moinhos de Vento

New P3 trial • Cardiovascular • Cognitive Disorders